PHILADELPHIA, PA — Vittoria Biotherapeutics, Inc. announced it will present interim clinical data from its first-in-human Phase 1 study of VIPER-101, a CD5-modulated autologous CAR-T therapy, at the upcoming American Society of Hematology (ASH) annual meeting in Orlando. The poster presentation, scheduled for December 7, will mark the first public release of clinical findings for the company’s lead program targeting relapsed or refractory T-cell lymphoma (TCL).
CEO Nicholas Siciliano said the early results show meaningful evidence that VIPER-101, built on the company’s Senza5 platform, may be capable of shifting the long-stagnant treatment landscape for TCL. “T-cell lymphoma has remained an exceptionally challenging disease with limited therapeutic advances for far too long,” Siciliano said. He added that the interim data demonstrate “the translatability and therapeutic benefits” of the company’s dual-population, CD5-targeted CAR-T approach.
A First Look at a Novel CAR-T Strategy
The Phase 1 VIPER-101 study is evaluating a gene-edited, autologous CAR-T therapy engineered to target CD5 — a marker present in more than 85% of TCL cases. Unlike classical CD5-directed CAR-T therapies, VIPER-101 incorporates a dual-population design and uses gene editing to disable CD5 signaling, aiming to counteract the immunosuppressive pathway that typically limits T-cell activity.
Preclinical models have shown superior potency and enhanced anti-tumor responses compared with earlier CD5-targeted constructs, setting expectations high for the interim human data.
Powered by a Rapid, Stemness-Focused Manufacturing Platform
Vittoria’s Senza5 platform underpins VIPER-101 and represents a key differentiator in engineered T-cell therapy development. The platform combines genetic editing with a five-day manufacturing process intended to preserve stemness and improve in vivo expansion and durability. By interrupting CD5-mediated immunosuppression, the platform is designed to amplify CAR-T cell activity across multiple tumor types.
The company says Senza5’s core mechanisms could be applied broadly across next-generation cellular therapies.
Presentation Details
- Title: First-in-human Phase 1 dose-finding study (VIPER-101) of dual-population autologous CD5-deleted anti-CD5 CAR-T (Senza5 CART5) cells in r/r T-cell lymphomas
- Date: December 7
- Time: 6–8 p.m. ET
- Session: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II
- Location: OCCC – West Halls B3–B4
- Publication Number: 4174
An electronic copy of the poster will be posted to Vittoria’s website after the session.
With VIPER-101 entering clinical view for the first time, the ASH presentation will be closely watched for early signs of efficacy, safety, and manufacturing scalability — all critical benchmarks for advancing an engineered T-cell therapy in one of the most treatment-resistant hematologic cancers.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.